Neurogene’s upcoming dosing of NGN-401 for Rett syndrome marks a significant milestone in addressing a rare and challenging neurological condition, reflecting the company’s commitment to innovative genetic therapies. With FDA discussions now complete, the Embolden™ trial is poised to generate critical data for patients and families eager for new treatment options.
NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the Company has completed discussions with the U.S. Food and Drug Administration (FDA) on its Embolden™ registrational trial protocol and plans to initiate dosing in the fourth quarter of 2025. In response to strong interest from the Rett syndrome community, the trial is expected to en
Source: Original Press Release
